Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

Eileen O'Reilly, MD
Published: Friday, Dec 15, 2017



Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
 


Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell TumorsApr 28, 20181.0
Publication Bottom Border
Border Publication
x